Compare · NVS vs PBYI
NVS vs PBYI
Side-by-side comparison of Novartis AG (NVS) and Puma Biotechnology Inc (PBYI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and PBYI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $293.40B, about 675.8x PBYI ($434.2M).
- Over the past year, NVS is up 34.6% and PBYI is up 150.7% - PBYI leads by 116.1 points.
- PBYI has been more active in the news (5 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 4 for PBYI).
- Company
- Novartis AG
- Puma Biotechnology Inc
- Price
- $153.72+0.64%
- $8.53+1.25%
- Market cap
- $293.40B
- $434.2M
- 1M return
- +1.89%
- +18.73%
- 1Y return
- +34.60%
- +150.74%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 1
- 5
- Recent ratings
- 25
- 4
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
Latest PBYI
- President and CEO Auerbach Alan H sold $364,051 worth of shares (44,058 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 0.60% to 7,261,671 units (SEC Form 4)
- Officer Hunt Douglas M sold $69,905 worth of shares (8,460 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 196,841 units (SEC Form 4)
- Chief Financial Officer Nougues Maximo F sold $77,557 worth of shares (9,386 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 230,637 units (SEC Form 4)
- SEC Form 144 filed by Puma Biotechnology Inc
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Wilson Troy Edward was granted 27,000 shares and sold $77,748 worth of shares (10,800 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 37% to 59,750 units (SEC Form 4)
- Director Stuglik Brian M was granted 27,000 shares and sold $58,311 worth of shares (8,100 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 20% to 113,858 units (SEC Form 4)
- Director Senderowicz Adrian sold $194,311 worth of shares (27,000 units at $7.20) as part of a pre-agreed trading plan and was granted 27,000 shares (SEC Form 4)
- Director Miller Michael Patrick was granted 27,000 shares, increasing direct ownership by 50% to 81,000 units (SEC Form 4)